Lexicon Pharmaceuticals (LXRX) News

Express News | Lexicon Pharmaceuticals - to Offer up to 1,257,856 Shares of Common Stock Issuable to Selling Stockholders - SEC Filing

BreakingsAug 7 05:09

10-Q: Lexicon Pharmaceuticals | 10-Q: Q2 2026 Earnings Report

SECAug 7 04:23

Analysts Conflicted on These Healthcare Names: Lexicon Pharmaceuticals (LXRX), Ascendis Pharma (ASND) and Lantheus (LNTH)

TipRanksAug 7 03:50

Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, Vs. FactSet Est of $0.05 Loss

07:56 AM EDT, 08/06/2026 (MT Newswires) -- Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05

MT NewswiresAug 6 19:56

Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over

BenzingaAug 6 19:48

Lexicon Pharma: NDA Resubmission Activities for ZYNQUISTA in Type 1 Diabetes Nearing Completion >LXRX

Lexicon Pharma: NDA Resubmission Activities for ZYNQUISTA in Type 1 Diabetes Nearing Completion >

Dow JonesAug 6 19:44

8-K: Lexicon Pharmaceuticals | 8-K: LEXICON PHARMACEUTICALS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES

SECAug 6 19:33

Express News | Lexicon Pharmaceuticals Q2 Net Income USD -31.775 Million

BreakingsAug 6 19:30

Express News | Lexicon Pharmaceuticals Q2 Operating Expenses USD 27.232 Million

BreakingsAug 6 19:30

Express News | Lexicon Pharmaceuticals Q2 Operating Income USD -26.54 Million

BreakingsAug 6 19:30

Express News | Lexicon Pharmaceuticals Q2 Product Revenue USD 680 Thousand

BreakingsAug 6 19:30

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027 NDA resubmission activities for ZYNQUISTA in type 1 diabetes nearing completion Phase 1 clinical development of LX9851

GlobeNewswireAug 6 19:30

Lexicon Pharma 2Q Loss/Shr 7c >LXRX

Lexicon Pharma 2Q Loss/Shr 7c >

Dow JonesAug 6 19:30

Lexicon Pharmaceuticals Q2 2026 Earnings Preview

Seeking AlphaAug 6 01:37

Earnings Preview: LXRX to Report Financial Results Pre-market on August 06

$Lexicon Pharmaceuticals(LXRX.US)$ is scheduled to release its financial results pre-market on August 06 ET. Earnings PreviewAnalysts estimate $Lexicon Pharmaceuticals(LXRX.US)$ to post revenue of

Futu NewsJul 31 12:45

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday,

GlobeNewswireJul 30 20:30

Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating

TipRanksJul 27 22:35

Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial

The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries. The primary efficacy endpoint will assess improvement in symptoms for the entire

BenzingaJul 27 20:35

Express News | Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

BreakingsJul 27 20:30

Piper Sandler Remains a Buy on Lexicon Pharmaceuticals (LXRX)

TipRanksJul 24 20:17